Skip to main content
    S

    Skye Bioscience, Inc. Common Stock (SKYE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.06
    -0.03 (-2.29%)

    Market Cap: $4.83M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Skye Bioscience, Inc. Common Stock (SKYE) Earnings: Report Dates and Results

    Updated Nov 16, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Skye Bioscience, Inc. Common Stock (SKYE) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Skye Bioscience, Inc. Common Stock reported EPS of -$2.56, below the -$1.12 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    25%(3/12)
    Avg Surprise
    -16.13%

    Upcoming Estimates

    Reports Mar 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$1.09
    Range-$1.18 - -$0.92
    5 analysts
    Revenue Consensus
    N/A
    RangeN/A
    5 analysts

    Next Report

    SKYE has an expected report date of Mar 8, 2027.

    SKYE Earnings Call

    The latest SKYE earnings call transcript on file is labeled 2025Q3.

    Read the 2025Q3 transcript

    Earnings History

    Of the 12 quarters below that had an estimate, SKYE beat 3, missed 7 and matched 2. The widest gap in the table came in the quarter ended Sep 30, 2026, when EPS landed 128.57% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$2.56-$1.12-$1.12 - -$1.12-128.57%MissN/A10 up, 0 downNov 16, 2026
    Jun 30, 2026-$0.27-$0.29-$0.36 - -$0.14+6.90%BeatN/A60 up, 1 downAug 14, 2026
    Mar 31, 2026-$0.32-$0.32-$0.51 - -$0.180.00%In lineN/A61 up, 2 downMay 11, 2026
    Dec 31, 2025-$2.95-$2.45-$2.88 - -$1.84-20.20%MissN/A60 up, 0 downMar 10, 2026
    Sep 30, 2025-$0.32-$0.32-$0.43 - -$0.240.00%In lineN/A60 up, 0 downNov 10, 2025
    Jun 30, 2025-$0.44-$0.34N/A-29.41%MissN/A40 up, 2 downAug 7, 2025
    Mar 31, 2025-$0.28-$0.29-$0.31 - -$0.26+3.45%BeatN/A41 up, 2 downMay 8, 2025
    Dec 31, 2024-$0.29-$0.29-$0.34 - -$0.23-2.18%MissN/A62 up, 0 downMar 20, 2025
    Sep 30, 2024-$0.10-$0.25-$0.34 - -$0.17+60.00%BeatN/A60 up, 0 downNov 7, 2024
    Jun 30, 2024-$0.20-$0.19-$0.26 - -$0.14-5.26%MissN/A40 up, 0 downAug 9, 2024
    Mar 31, 2024-$0.18-$0.16-$0.16 - -$0.16-12.50%MissN/A10 up, 0 downMay 10, 2024
    Dec 31, 2023-$0.63-$0.38-$0.38 - -$0.38-65.79%MissN/A10 up, 0 downMar 22, 2024
    Sep 30, 2023-$3.17N/AN/AN/AN/AN/AN/AN/ANov 13, 2023
    Jun 30, 2023$0.00N/AN/AN/AN/AN/AN/AN/AAug 7, 2023
    Mar 31, 2023-$0.01N/AN/AN/AN/AN/AN/AN/AMay 11, 2023
    Dec 31, 2022-$0.01N/AN/AN/AN/AN/AN/AN/AMar 31, 2023
    Sep 30, 2022-$0.01N/AN/AN/AN/AN/AN/AN/ANov 14, 2022
    Jun 30, 2022-$0.01N/AN/AN/AN/AN/AN/AN/AAug 15, 2022
    Mar 31, 2022-$0.01N/AN/AN/AN/AN/AN/AN/AMay 6, 2022
    Dec 31, 2021-$0.01N/AN/AN/AN/AN/AN/AN/AMar 25, 2022
    Sep 30, 2021$0.00N/AN/AN/AN/AN/AN/AN/ANov 10, 2021
    Jun 30, 2021-$0.01N/AN/AN/AN/AN/AN/AN/AAug 6, 2021
    Mar 31, 2021-$0.01N/AN/AN/AN/AN/AN/AN/AMay 7, 2021
    Dec 31, 2020-$0.01N/AN/AN/AN/A-133.3%N/AN/AMar 1, 2021
    Sep 30, 2020-$0.01N/AN/AN/AN/AN/AN/AN/ANov 6, 2020
    Jun 30, 2020-$0.01N/AN/AN/AN/A-112.5%N/AN/AAug 13, 2020
    Mar 31, 2020-$0.01N/AN/AN/AN/AN/AN/AN/AMay 8, 2020
    Dec 31, 2019$0.03N/AN/AN/AN/AN/AN/AN/AMar 20, 2020
    Sep 30, 2019-$0.04N/AN/AN/AN/AN/AN/AN/ANov 13, 2019
    Jun 30, 2019$0.08N/AN/AN/AN/AN/AN/AN/AAug 9, 2019
    Mar 31, 2019-$0.11N/AN/AN/AN/AN/AN/AN/AMay 9, 2019
    Dec 31, 2018-$0.05N/AN/AN/AN/AN/AN/AN/AMar 14, 2019
    Sep 30, 2018-$0.02N/AN/AN/AN/AN/AN/AN/ANov 13, 2018
    Jun 30, 2018-$0.02N/AN/AN/AN/AN/AN/AN/AAug 10, 2018
    Mar 31, 2018-$0.09N/AN/AN/AN/AN/AN/AN/AMay 15, 2018
    Dec 31, 2017-$0.03N/AN/AN/AN/AN/AN/AN/AMar 19, 2018
    Sep 30, 2017-$0.02N/AN/AN/AN/AN/AN/AN/ANov 14, 2017
    Jun 30, 2017-$0.02N/AN/AN/AN/AN/AN/AN/AAug 11, 2017
    Mar 31, 2017-$0.02N/AN/AN/AN/AN/AN/AN/AMay 12, 2017
    Dec 31, 2016-$0.09N/AN/AN/AN/AN/AN/AN/AMar 10, 2017
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.99, after -$0.77 the year before. It was -$37.68 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.99N/A
    Dec 31, 2024-$0.77N/A
    Dec 31, 2023-$3.80N/A
    Dec 31, 2022-$0.04N/A
    Dec 31, 2021-$0.03N/A
    Dec 31, 2020-$0.04N/A
    Dec 31, 2019-$0.04N/A
    Dec 31, 2018-$0.18N/A
    Dec 31, 2017-$0.09N/A
    Dec 31, 2016-$37.68N/A

    Earnings Calls

    The 5 most recent earnings calls are listed below; the latest, 2025Q3 for the period ended Sep 30, 2025, runs about 7,200 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2025Q3Sep 30, 20257,18212
    2025Q2Jun 30, 20255,13311
    2025Q1Mar 31, 20255,81814
    2024Q4Dec 31, 20247,68014
    2024Q3Sep 30, 20246,14612

    2025Q3 Earnings Call

    Opening remarks

    Bernie Hertel Head of Investor Relations Hello, and thank you all for participating in today's call. Before we begin, I'd like to caution that comments made during this conference call will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements of Skye Bioscience, Inc.'s expectations regarding its development activities, timelines, and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date, and the company undertakes no obligation to revise or update any statements made today. I encourage you to review all of the company's filings with the Securities and Exchange concerning these and other matters. I'll now turn the call over to Kaitlyn Arsenault, Skye's CFO.

    Kaitlyn Arsenault CFO Thanks, Bernie. After the market closed today, we issued a release and filed Skye Bioscience, Inc.'s Form 10-Q with the Securities and Exchange Commission, outlining our quarterly financial results. We encourage you to reference our filings for the details of our financials and the risk factors described therein. I will now provide a brief overview of our key financial results for the third quarter ended September 30, 2025. We ended the third quarter with cash and cash equivalents and short-term investments totaling $35.3 million. We expect our current working capital to fund operations and key clinical milestones into 2027. This includes the completion of the extension of our Phase 2a study for Nimazumab, certain manufacturing, and preparatory clinical activities needed to initiate the next study. In addition, our runway continues to include a modest discovery R&D budget, the dose concentration, and process intensification work required to support our expected TPP and scale and support later-stage studies for Nimazumab. R&D expenses for the three months ended September 30, 2025, were $9.4 million as compared to $4.9 million for the same period in 2024. The increase was primarily due to contract manufacturing, clinical trial costs associated with our obesity study for Nolasimab, discovery R&D expenses, salary and stock-based compensation expense, and consulting, advisory, and professional fees. General and administrative expenses for the three months ended September 30, 2025, were $3.9 million as compared to $4.6 million for the same period in 2024. The decrease was primarily related to decreases in consulting, advisory, and professional fees, recruitment fees, salaries, and stock-based compensation expense. Our net loss for the three months ended September 30, 2025, totaled $12.8 million, including non-cash share-based compensation expense of $1.9 million, compared to $3.9 million for the same period in 2024 with non-cash share-based compensation expense of $1.9 million.

    Frequently Asked Questions About SKYE

    When is Skye Bioscience, Inc. Common Stock's next earnings date?

    Skye Bioscience, Inc. Common Stock's next earnings report is expected for Mar 8, 2027.

    Did SKYE beat earnings estimates last quarter?

    No. Skye Bioscience, Inc. Common Stock reported EPS of -$2.56 for the quarter ended Sep 30, 2026, below the -$1.12 estimate by 128.57%.

    What EPS do analysts expect from SKYE next quarter?

    The consensus EPS estimate for Skye Bioscience, Inc. Common Stock for the quarter ending Dec 31, 2026 is -$1.09 from 5 analysts, with estimates from -$1.18 to -$0.92.

    How often does SKYE beat earnings estimates?

    Skye Bioscience, Inc. Common Stock beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -21.25%.